Status:
NOT_YET_RECRUITING
Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion
Lead Sponsor:
University Hospital Sestre Milosrdnice
Collaborating Sponsors:
Ever Neuro Pharma GmbH
Conditions:
Basilar Artery Occlusion
Posterior Circulation Brain Infarction
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
The standard therapy for acute ischemic posterior circulation stroke (PCS) often leads to poor functional outcomes and high mortality rates, despite all advances in reperfusion therapy. Recent trials ...
Detailed Description
The investigators plan to conduct a prospective, single-center, single-arm, open-label study with 20 acute basilar artery occlusion patients with premorbid modified Rankin Score (mRS) ≤3, treated with...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Acute basilar artery occlusion confirmed on MSCT/ MR angiography
- Premorbid mRS ≤ 3
- Signed written consent
Exclusion
- Hypersensitivity to one of the components of the drug
- Breastfeeding and pregnancy
- Epilepsy, epileptic seizure
- Severe renal impairment (grade IV and V)
- Ischemic stroke in the previous three months
- Metastatic cancer
- Sepsis or a severe infection on admission
- Acute coronary syndrome, pulmonary embolism, and deep venous thrombosis on admission
Key Trial Info
Start Date :
July 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06489925
Start Date
July 1 2024
End Date
May 1 2026
Last Update
July 9 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.